Pearce Edward J
Department of Pathobiology, Room 203D, Johnson Pavilion, 3610 Hamilton Walk, University of Pennsylvania, Philadelphia, PA 19104-6076, USA.
Acta Trop. 2003 May;86(2-3):309-13. doi: 10.1016/s0001-706x(03)00062-7.
Schistosomiasis continues to be a significant health problem, especially in Africa. While the recent World Health Assembly resolution to apply mass drug treatment of school age children in endemic areas is a very promising development, a preferable long-term solution would be provided by a protective vaccine. Encouragingly, one vaccine, Bilhvax, is in phase II trials. However, there is a danger that momentum towards the goal of developing a vaccine against schistosomiasis is dissipating. This article reviews the current situation in this important area of schistosomiasis research.
血吸虫病仍然是一个重大的健康问题，尤其是在非洲。虽然世界卫生大会最近通过的关于在流行地区对学龄儿童进行大规模药物治疗的决议是一个非常有前景的进展，但一种保护性疫苗将提供更可取的长期解决方案。令人鼓舞的是，一种名为Bilhvax的疫苗正在进行二期试验。然而，开发抗血吸虫病疫苗这一目标的发展势头有消散的危险。本文回顾了血吸虫病研究这一重要领域的现状。
